Variables | All patients N = 52 | Hormone receptor positive (ER+, PgR±, HER2-) N = 39 | HER2 positive (HER2+, ER±, PgR±) N = 7 | Triple-negative (ER-, PgR-, HER2-) N = 4 | P-value |
---|---|---|---|---|---|
Age at MBC diagnosis | |||||
Median (range) | 60 (40–83) | 64 (40–83) | 57 (45–76) | 51 (42–57) | 0.10 |
< 50 years | 12 | 9 | 1 | 2 | 0.45 |
≥ 50 years | 40 | 30 | 6 | 2 | |
Time to recurrence | |||||
Median (range in years) | 5.3 (0–27.6) | 5.1 (0–27.6) | 1.7 (0–5.3) | 1.3 (1.2–2.3) | 0.007 |
Nr of patients with stage IV at diagnosis | 9 | 5 | 4 | 0 | 0.44 |
NHG | |||||
I | 2 | 2 | 0 | 0 | 0.50 |
II | 23 | 18 | 2 | 2 | |
III | 18 | 13 | 2 | 2 | |
Unknown | 9 | 6 | 3 | 0 | |
Ki67 | |||||
Low (≤20%) | 5 | 5 | 0 | 0 | 0.071 |
High (>20%) | 16 | 8 | 4 | 4 | |
Unknown | 31 | 26 | 3 | 0 | |
First-line systemic therapy | |||||
Endocrine only | 11 | 11 | 0 | 0 | b |
Chemotherapy only | 35 | 28 | 1 | 4 | |
HER2-directed (with chemotherapy) | 6 | 0 | 6 | 0 | |
Metastatic site at BL | |||||
Locoregional | 3 | 1 | 0 | 2 | 0.30 |
Skeletal only | 19 | 15 | 3 | 1 | |
CNS | 1 | 1 | 0 | 0 | |
Visceral (two with unknown subtype) | 28 | 21 | 4 | 1 | |
Other locations | 1 | 1 | 0 | 0 | |
Number of metastatic locations | |||||
1–2 | 32 | 24 | 4 | 3 | 0.74 |
3 or more | 20 | 15 | 3 | 1 |